Bitcoin price today: tumbles below $90k as Fed cut doubts spark risk-off mood
Investing.com -- Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a third quarter loss of -$0.04 per share, missing analyst estimates of -$0.03, while revenue came in at $530,000, below the consensus estimate of $1.39 million. Despite the earnings miss, shares rose 5% in after-hours trading Thursday, as investors focused on promising clinical data from the company’s hepatitis B treatment.
The biopharmaceutical company highlighted new analysis of its imdusiran (AB-729) clinical data, showing that 46% of Phase 2a patients met criteria to discontinue all treatment, with 94% of long-term follow-up patients remaining off treatment for up to over two years. Additionally, all HBV DNA positive patients in Phase 1b achieved HBV DNA levels below quantification after only 18 weeks of therapy.
"The strength of our third quarter performance reflects our disciplined focus on executing strategic priorities," said Lindsay Androski, President and CEO of Arbutus. "We remain dedicated to accelerating the development and potential approval of imdusiran."
Revenue decreased from $1.3 million in the same quarter last year, primarily due to a decline in license royalty revenues from Alnylam’s sales of ONPATTRO. Research and development expenses fell to $5.8 million from $14.3 million YoY, while general and administrative expenses decreased to $3.0 million from $4.5 million, reflecting the company’s cost-cutting efforts.
Arbutus maintained a strong financial position with $93.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, compared to $122.6 million at the end of 2024. The company used $35.0 million in operating activities during the first nine months of 2025.
The company also provided updates on its ongoing litigation against Moderna and Pfizer/BioNTech regarding its LNP technology patents, with the Moderna U.S. trial scheduled for March 2026 and a favorable claim construction ruling in the Pfizer-BioNTech litigation issued in September 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.